吡咯达霉素A和B的抗肿瘤活性。
Antitumor activity of pyrindamycins A and B.
作者信息
Ishii S, Nagasawa M, Kariya Y, Yamamoto H, Inouye S, Kondo S
机构信息
Pharmaceutical Research Laboratory, Meiji Seika Kaisha, Ltd., Yokohama, Japan.
出版信息
J Antibiot (Tokyo). 1989 Nov;42(11):1713-7. doi: 10.7164/antibiotics.42.1713.
Pyrindamycins A(1) and B(2) exhibited stronger cytotoxic activities than doxorubicin towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells. Pyrindamycins A and B were also active in vivo against P388/ADR, a multidrug-resistant tumor cell line. Intracellular accumulation of pyrindamycins A and B in P388/ADR was the same as in P388. These antibiotics strongly inhibited DNA synthesis compared with RNA or protein synthesis. They showed significant therapeutic effects towards murine leukemia, but not to solid tumors.
吡咯达霉素A（1）和B（2）对鼠类和人类肿瘤细胞系，尤其是对阿霉素耐药细胞，表现出比阿霉素更强的细胞毒性活性。吡咯达霉素A和B在体内对多药耐药肿瘤细胞系P388/ADR也有活性。吡咯达霉素A和B在P388/ADR细胞内的蓄积与在P388细胞内的蓄积相同。与RNA或蛋白质合成相比，这些抗生素强烈抑制DNA合成。它们对鼠类白血病显示出显著的治疗效果，但对实体瘤无效。
Zotero 插件